MX2009004028A - Sal acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-be ta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona y metodos de preparacion. - Google Patents

Sal acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-be ta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona y metodos de preparacion.

Info

Publication number
MX2009004028A
MX2009004028A MX2009004028A MX2009004028A MX2009004028A MX 2009004028 A MX2009004028 A MX 2009004028A MX 2009004028 A MX2009004028 A MX 2009004028A MX 2009004028 A MX2009004028 A MX 2009004028A MX 2009004028 A MX2009004028 A MX 2009004028A
Authority
MX
Mexico
Prior art keywords
ribofuranosyl
deoxy
acetyl
amino
sulfonic acid
Prior art date
Application number
MX2009004028A
Other languages
English (en)
Inventor
Fritz Blatter
Gregory J Haley
Erik J Rueden
David Kucera
Tingmin Wag
Martin Viertelhaus
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of MX2009004028A publication Critical patent/MX2009004028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la sal ácido p-toluensulfónico de 5-amino-3-(2´-O-acetil-3´-desoxi-ß-D-ribo-furanosil)-3H-tiazolo [4,5-d]pirimidin-2-ona y a su uso en el tratamiento de condiciones tales como infecciones virales, tumores y cáncer. Se describe también un método para preparar la sal ácido p-toluensulfónico de 5-amino-3-(2´-O-acetil-3´-desoxi-ß-D-ribofura nosil)-3H-tiazolo[4,5-d]pirimidin-2-ona y métodos para producir compuestos de furanosa que son intermediarios útiles en la preparación de compuestos farmacéuticos tales como sal ácido p-toluensulfónico de 5-amino-3-(2´-O-acetil-3´-desoxi-ß-D-ribofura nosil)-3H-tiazolo[4,5-d]pirimidin-2-ona y similares.
MX2009004028A 2006-10-17 2007-10-16 Sal acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-be ta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona y metodos de preparacion. MX2009004028A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
PCT/US2007/081526 WO2008140549A1 (en) 2006-10-17 2007-10-16 P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION

Publications (1)

Publication Number Publication Date
MX2009004028A true MX2009004028A (es) 2009-05-11

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004028A MX2009004028A (es) 2006-10-17 2007-10-16 Sal acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-be ta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona y metodos de preparacion.

Country Status (25)

Country Link
US (2) US7928085B2 (es)
EP (1) EP2076132B1 (es)
JP (2) JP5279715B2 (es)
KR (2) KR101486444B1 (es)
AR (1) AR063484A1 (es)
AU (1) AU2007353381B2 (es)
BR (1) BRPI0717741A2 (es)
CA (2) CA2666537C (es)
CY (1) CY1113368T1 (es)
DK (1) DK2076132T3 (es)
DO (1) DOP2007000131A (es)
EA (1) EA017005B1 (es)
ES (1) ES2390930T3 (es)
HK (1) HK1132429A1 (es)
IL (2) IL198180A (es)
MX (1) MX2009004028A (es)
MY (1) MY150408A (es)
NO (1) NO20091598L (es)
NZ (1) NZ576408A (es)
PE (1) PE20081105A1 (es)
PL (1) PL2076132T3 (es)
PT (1) PT2076132E (es)
TW (1) TWI415854B (es)
UY (1) UY30650A1 (es)
WO (1) WO2008140549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
UA124184C2 (uk) 2014-12-08 2021-08-04 Ф. Хоффманн-Ля Рош Аг 3-ЗАМІЩЕНІ 5-АМІНО-6H-ТІАЗОЛО[4,5-d]ПІРИМІДИН-2,7-ДІОНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ І ПРОФІЛАКТИКИ ВІРУСНИХ ІНФЕКЦІЙ
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
EP3845227A1 (en) 2015-03-16 2021-07-07 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN107743491B (zh) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
JP6839104B2 (ja) 2015-06-30 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
EP3568400A1 (en) * 2017-01-06 2019-11-20 H. Hoffnabb-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2-7-DIONE COMPOUNDS
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 １―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc ２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
KR100718371B1 (ko) * 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
WO2004052892A1 (en) 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
US20080070852A1 (en) * 2004-06-07 2008-03-20 Averett Devron R 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof
AR052995A1 (es) * 2004-12-17 2007-04-18 Anadys Pharmaceuticals Inc Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
JP5550234B2 (ja) * 2006-12-08 2014-07-16 株式会社エーピーアイ コーポレーション フラノース誘導体の製造方法

Also Published As

Publication number Publication date
KR20090074237A (ko) 2009-07-06
CA2666537A1 (en) 2008-11-20
EP2076132A1 (en) 2009-07-08
JP5703334B2 (ja) 2015-04-15
KR101515077B1 (ko) 2015-04-24
IL223126A (en) 2016-08-31
KR20140119203A (ko) 2014-10-08
CY1113368T1 (el) 2016-06-22
PT2076132E (pt) 2012-10-03
UY30650A1 (es) 2008-05-31
WO2008140549A1 (en) 2008-11-20
EP2076132A4 (en) 2011-05-04
US7928085B2 (en) 2011-04-19
AR063484A1 (es) 2009-01-28
EA017005B1 (ru) 2012-09-28
MY150408A (en) 2014-01-15
JP2010506947A (ja) 2010-03-04
US20110172447A1 (en) 2011-07-14
AU2007353381A1 (en) 2008-11-20
PL2076132T3 (pl) 2013-01-31
IL198180A0 (en) 2009-12-24
PE20081105A1 (es) 2008-08-15
JP2013166782A (ja) 2013-08-29
BRPI0717741A2 (pt) 2014-04-08
DK2076132T3 (da) 2012-09-10
JP5279715B2 (ja) 2013-09-04
DOP2007000131A (es) 2008-09-15
AU2007353381B2 (en) 2013-07-04
NO20091598L (no) 2009-07-10
IL223126A0 (en) 2012-12-31
CA2666537C (en) 2015-12-08
KR101486444B1 (ko) 2015-01-26
EA200970387A1 (ru) 2009-10-30
IL198180A (en) 2015-06-30
EP2076132B1 (en) 2012-07-11
CA2898225A1 (en) 2008-11-20
ES2390930T3 (es) 2012-11-19
TWI415854B (zh) 2013-11-21
US8193342B2 (en) 2012-06-05
US20090197826A1 (en) 2009-08-06
HK1132429A1 (es) 2010-02-26
NZ576408A (en) 2012-04-27
TW200833699A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
MX2009004028A (es) Sal acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-be ta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona y metodos de preparacion.
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
TN2009000215A1 (en) Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
BRPI0517426A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
WO2006066074A3 (en) Lung-targeted drugs
TW200630366A (en) Organic compounds
WO2006124413A3 (en) Methods for treating drug resistant cancer
NO20055209L (no) Peptabody for cancerbehandling
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2010022201A3 (en) Folinic acid derivatives for promoting bone growth
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth
MX2007014297A (es) Derivados de purina y su uso para el tratamiento de enfermedades autoinmunes.
WO2004060902A3 (en) Novel nucleoside transport inhibitors
WO2007039919A8 (en) Crystalline forms of anastrozole
EA201170702A1 (ru) Способ получения производных дезоксирибофуранозы
EA200800575A1 (ru) Производные 5-пиридинил-1-азабицикло [3.2.1] октана, их получение и их применение в терапии
WO2010011599A3 (en) Pimethixene derivatives for promoting bone growth
WO2008087340A3 (fr) UTILISATION D' OLIGO-β-(1,3)-GLUCANES MODIFIES POUR LE TRAITEMENT DE MALADIES DU SYSTEME IMMUNITAIRE, OLIGO-β-(1,3)-GLUCANE-(1,3)- MANNOSE, OLIGO-β-(1.3)-GLUCANE-(1,3)- MANNITOL ET LEURS DERIVES, LEURS PROCEDES DE PREPARATION ET MEDICAMENTS LES CONTENANT
ZA200903372B (en) P-toluene sulfonic acid salt of 5-amino-3-(2'-O-acetyl-3'-deoxy-²-D-ribofuranosyl)-3H-thizaole [4, 5-D] pyrimidine-2-one and methods for preparation
WO2010019549A3 (en) Indoprofen derivatives for promoting bone growth

Legal Events

Date Code Title Description
FG Grant or registration